Cancer nanomedicine: a review of nano-therapeutics and challenges ahead

Cancer is known as the most dangerous disease in the world in terms of mortality and lack of effective treatment. Research on cancer treatment is still active and of great social importance. Since 1930, chemotherapeutics have been used to treat cancer. However, such conventional treatments are assoc...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances 2023-03, Vol.13 (13), p.866-8629
Main Authors: Nirmala, M. Joyce, Kizhuveetil, Uma, Johnson, Athira, G, Balaji, Nagarajan, Ramamurthy, Muthuvijayan, Vignesh
Format: Article
Language:English
Subjects:
Bioavailability
Cancer
Cancer therapies
Chemistry
FDA approval
Health services
Lipids
Nanoemulsions
Nanomaterials
Nanoparticles
Side effects
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer is known as the most dangerous disease in the world in terms of mortality and lack of effective treatment. Research on cancer treatment is still active and of great social importance. Since 1930, chemotherapeutics have been used to treat cancer. However, such conventional treatments are associated with pain, side effects, and a lack of targeting. Nanomedicines are an emerging alternative due to their targeting, bioavailability, and low toxicity. Nanoparticles target cancer cells via active and passive mechanisms. Since FDA approval for Doxil®, several nano-therapeutics have been developed, and a few have received approval for use in cancer treatment. Along with liposomes, solid lipid nanoparticles, polymeric nanoparticles, and nanoemulsions, even newer techniques involving extracellular vesicles (EVs) and thermal nanomaterials are now being researched and implemented in practice. This review highlights the evolution and current status of cancer therapy, with a focus on clinical/pre-clinical nanomedicine cancer studies. Insight is also provided into the prospects in this regard. Approaches to overcome the challenges of cancer nanomedicine drug discovery process.
ISSN:2046-2069
2046-2069
DOI:10.1039/d2ra07863e